Everest Medicines
China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
July 18, 2024Medical Communications China, Everest Medicines, NMPA, Nephrology
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
